What is Cavion?
Cavion, with operations in Charlottesville, VA, and Cambridge, MA, is dedicated to pioneering therapies that modulate the T-type calcium channel. The company's focus lies in addressing chronic and rare neurological diseases by restoring natural brain rhythms. Its therapeutic candidates are being developed for conditions including essential tremor, Parkinson's disease tremor, neuropathic pain, and epilepsy with absence seizures, positioning Cavion as a key player in the neurodegenerative disease therapeutic space.
How much funding has Cavion raised?
Cavion has raised a total of $31.5M across 2 funding rounds:
Private Equity
$5M
Series A
$26.5M
Private Equity (2015): $5M, investors not publicly disclosed
Series A (2017): $26.5M led by Enso Ventures, Lilly Ventures, and Novartis Venture Fund
Key Investors in Cavion
Enso Ventures
Enso Ventures is a venture capital firm specializing in high-technology and bio-tech companies, providing capital and expertise to accelerate commercial development and growth.
Lilly Ventures
Lilly Ventures, rooted in the scientific tradition of Eli Lilly and Company, partners with life science innovators, offering financial and intellectual resources to accelerate their success.
Novartis Venture Fund
Novartis Venture Fund, part of the global pharmaceutical giant Novartis, invests in innovative healthcare solutions and cutting-edge medical technologies.
What's next for Cavion?
The recent major strategic investment signifies a critical growth phase for Cavion, likely enabling the company to advance its clinical trials and potentially move towards commercialization. This substantial backing from investors suggests strong confidence in Cavion's technology and its potential to address significant unmet medical needs in neurology. The company is poised to leverage this capital for further research and development, aiming to solidify its position in the competitive biotechnology landscape.
See full Cavion company page
